FMP
electroCore, Inc.
ECOR
NASDAQ
electroCore, Inc., a commercial stage medical device company, engages in the development and commercialization of a range of non-invasive vagus nerve stimulation (nVNS) therapies. The company is developing gammaCore, a prescription-only nVNS therapy for the acute treatment of pain associated with migraine and episodic cluster headache in adults. Its lead product is gammaCore Sapphire, a rechargeable and reloadable handheld device for regular or intermittent use over many years. The company was incorporated in 2005 and is headquartered in Rockaway, New Jersey.
15.27 USD
0.75 (4.91%)
We are unable to load the chart at this time.
Mr. Daniel S. Goldberger
Healthcare
Medical - Devices
NASDAQ
electroCore, Inc., a commercial stage medical device company, engages in the development and commercialization of a range of non-invasive vagus nerve stimulation (nVNS) therapies. The company is developing gammaCore, a prescription-only nVNS therapy for the acute treatment of pain associated with migraine and episodic cluster headache in adults. Its lead product is gammaCore Sapphire, a rechargeable and reloadable handheld device for regular or intermittent use over many years. The company was incorporated in 2005 and is headquartered in Rockaway, New Jersey.
0001560258
US28531P2020
28531P103
200 Forge Way
973 290 0097
US
68
Jun 22, 2018
We are unable to load the chart at this time.
We are unable to load the chart at this time.
0001560258
NASDAQ
Medical - Devices
Healthcare
28531P103
US28531P2020
US
15.27
0.56
109.95k
100.09M
-
5.25-17.843
1.13
-
-
-
-
-8.78
-
https://www.electrocore.com
We are unable to load this data!
Financial Information
Financial Summary Real-Time Price
Financial Statements
Financial Quarter Statements
Ratios Analysis
Dupont Analysis
Free Cashflow
Operating Data
Balance Sheet Data
Financial Modelling
Discounted Cashflow Model
Discounted Cashflow Model Levered
Free Cashflow Build-Up
Terminal Value
Intrinsic Value
Weighted Average Cost of Capital
Market Information
Stock Value
It looks like there's no news available.